Lisata Therapeutics Inc Gains Positive Outlook in Recent Research Update

On August 18, 2025, First Berlin Equity Research GmbH reaffirmed a "BUY" recommendation for Lisata Therapeutics Inc, maintaining a target price of USD 15.00. This followed the release of the company's H1/25 financial results, which outperformed expectations. Analyst Christian Orquera noted progress in Lisata's pipeline, especially concerning two primary pancreatic cancer trials.

The ASCEND phase 2b trial highlighted positive signals in median progression-free survival and objective response rate for metastatic pancreatic ductal adenocarcinoma. However, the overall survival benefit was slightly less pronounced than earlier data indicated, suggesting a need for further dose optimization.

The iLSTA trial also showed promising preliminary results, enhancing confidence in certepetide's effectiveness, particularly in making non-resectable pancreatic tumors more responsive to immunotherapy. Final results are expected in Q1 2026.